215 related articles for article (PubMed ID: 20844611)
1. Comparison of antimicrobial agents as therapy for experimental endocarditis: caused by methicillin-resistant Staphylococcus aureus.
Sacar M; Sacar S; Cevahir N; Onem G; Teke Z; Asan A; Turgut H; Adali F; Kaleli I; Susam I; Yaylali YT; Baltalarli A
Tex Heart Inst J; 2010; 37(4):400-4. PubMed ID: 20844611
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.
Dailey CF; Dileto-Fang CL; Buchanan LV; Oramas-Shirey MP; Batts DH; Ford CW; Gibson JK
Antimicrob Agents Chemother; 2001 Aug; 45(8):2304-8. PubMed ID: 11451689
[TBL] [Abstract][Full Text] [Related]
3. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.
Drago L; Nicola L; De Vecchi E
Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of linezolid, quinupristin-dalfopristin, vancomycin, teicoplanin, moxifloxacin and mupirocin against methicillin-resistant Staphylococcus aureus: comparative evaluation by the E test and a broth microdilution method.
Abb J
Diagn Microbiol Infect Dis; 2002 Aug; 43(4):319-21. PubMed ID: 12151194
[TBL] [Abstract][Full Text] [Related]
5. Bactericidal activities of daptomycin, quinupristin-dalfopristin, and linezolid against vancomycin-resistant Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.
Cha R; Brown WJ; Rybak MJ
Antimicrob Agents Chemother; 2003 Dec; 47(12):3960-3. PubMed ID: 14638509
[TBL] [Abstract][Full Text] [Related]
6. Treatment of experimental endocarditis due to erythromycin-susceptible or -resistant methicillin-resistant Staphylococcus aureus with RP 59500.
Entenza JM; Drugeon H; Glauser MP; Moreillon P
Antimicrob Agents Chemother; 1995 Jul; 39(7):1419-24. PubMed ID: 7492078
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus.
Chiang FY; Climo M
Antimicrob Agents Chemother; 2003 Sep; 47(9):3002-4. PubMed ID: 12937013
[TBL] [Abstract][Full Text] [Related]
8. Vascular graft infection by Staphylococcus aureus: efficacy of linezolid, teicoplanin and vancomycin systemic prophylaxis protocols in a rat model.
Atahan E; Katrancioglu N; Oztop Y; Tuncer E; Ozer H; Manduz S; Engin E; Yalta TD; Berkan O; Dogan K
Cardiovasc J Afr; 2009; 20(2):122-5. PubMed ID: 19421648
[TBL] [Abstract][Full Text] [Related]
9. [Evaluation of antibiotic susceptibilities and VISA-VRSA rates among MRSA strains isolated from hospitalized patients in intensive care units of hospitals in seven provinces of Turkey].
Cesur S; Irmak H; Simşek H; Cöplü N; Kılıç H; Arslan U; Bayramoğlu G; Baysan BO; Gülay Z; Hoşoğlu S; Berktaş M; Gencer S; Demiröz AP; Esen B; Karabiber N; Aydın F; Yalçın AN
Mikrobiyol Bul; 2012 Jul; 46(3):352-8. PubMed ID: 22951647
[TBL] [Abstract][Full Text] [Related]
10. [Activity of vancomycin, teicoplanin and linezolid in methicillin resistant coagulase-negative Staphylococci isolates from paediatric blood cultures].
Fajardo Olivares M; Hidalgo Orozco R; Rodríguez Garrido S; Gaona Álvarez C; Sánchez Silos RM; Hernández Rastrollo R; Martínez Tallo E; Cordero Carrasco JL
Rev Esp Quimioter; 2012 Mar; 25(1):25-30. PubMed ID: 22488538
[TBL] [Abstract][Full Text] [Related]
11. Antistaphylococcal activities of quinupristin/dalfopristin in vitro across platelet-fibrin matrices and in experimental endocarditis.
Berthaud N; Huet Y; Diallo N; Desnottes JF
J Antimicrob Chemother; 1997 May; 39 Suppl A():93-8. PubMed ID: 9511071
[TBL] [Abstract][Full Text] [Related]
12. [Staphylococcus aureus and antibiotic resistance].
Sancak B
Mikrobiyol Bul; 2011 Jul; 45(3):565-76. PubMed ID: 21935792
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacies of quinupristin-dalfopristin, linezolid, vancomycin, and ciprofloxacin in treatment, using the antibiotic-lock technique, of experimental catheter-related infection due to Staphylococcus aureus.
Giacometti A; Cirioni O; Ghiselli R; Orlando F; Mocchegiani F; Silvestri C; Licci A; De Fusco M; Provinciali M; Saba V; Scalise G
Antimicrob Agents Chemother; 2005 Oct; 49(10):4042-5. PubMed ID: 16189078
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of linezolid & quinupristin/dalfopristin against Gram-positive cocci.
Tünger A; Aydemir S; Uluer S; Cilli F
Indian J Med Res; 2004 Dec; 120(6):546-52. PubMed ID: 15654141
[TBL] [Abstract][Full Text] [Related]
15. In vivo efficacy of continuous infusion versus intermittent dosing of linezolid compared to vancomycin in a methicillin-resistant Staphylococcus aureus rabbit endocarditis model.
Jacqueline C; Batard E; Perez L; Boutoille D; Hamel A; Caillon J; Kergueris MF; Potel G; Bugnon D
Antimicrob Agents Chemother; 2002 Dec; 46(12):3706-11. PubMed ID: 12435665
[TBL] [Abstract][Full Text] [Related]
16. Sequential regimen for early post-surgical infective endocarditis due to methicillin-resistant Staphylococcus aureus (MRSA), unresponsive to standard antibiotic therapy: a case report.
Viale P; Scolari C; Colombini P; Cristini F; Cadeo B; Pagani L
J Chemother; 2002 Oct; 14(5):526-9. PubMed ID: 12462433
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and pharmacodynamics of linezolid, alone and in combination with rifampicin, in an experimental model of methicillin-resistant Staphylococcus aureus endocarditis.
Tsaganos T; Skiadas I; Koutoukas P; Adamis T; Baxevanos N; Tzepi I; Pelekanou A; Giamarellos-Bourboulis EJ; Giamarellou H; Kanellakopoulou K
J Antimicrob Chemother; 2008 Aug; 62(2):381-3. PubMed ID: 18445576
[TBL] [Abstract][Full Text] [Related]
18. Antibiotic regimen including linezolid for treating prosthetic valve endocarditis with cerebral embolism due to methicillin-susceptible Staphylococcus aureus after failure with oxacillin and teicoplanin.
Brugraro P; Eseme F; Morelli E; Fiscon M; Rosini G; Belussi F; Ebo F; Petrucci A; Tenderini P; Raise E
Infez Med; 2009 Dec; 17(4):240-3. PubMed ID: 20046105
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of telavancin in the treatment of experimental endocarditis due to glycopeptide-intermediate Staphylococcus aureus.
Miró JM; García-de-la-Mària C; Armero Y; de-Lazzari E; Soy D; Moreno A; del Rio A; Almela M; Mestres CA; Gatell JM; Jiménez-de-Anta MT; Marco F;
Antimicrob Agents Chemother; 2007 Jul; 51(7):2373-7. PubMed ID: 17485502
[TBL] [Abstract][Full Text] [Related]
20. In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.
Jevitt LA; Smith AJ; Williams PP; Raney PM; McGowan JE; Tenover FC
Microb Drug Resist; 2003; 9(4):389-93. PubMed ID: 15000746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
